title: Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
abstract: Mutations in the connection domain (CD) of reverse transcriptase have been implicated in reverse transcriptase inhibitor (RTI) resistance, but this is controversial and little is known in non-B subtype HIV-1. We determined CD mutations prevalence in a population infected predominantly with CRF02_AG and investigated associations with phenotypic RTI resistance. Detected CD mutations were G335D (82.3%), A371V (69.8%), E399D (9.4%), N348I (5.2%), V365I (4.2), Y318F (2.1%), G333E (2.1%), and A360V (2.1%). Mutations were largely polymorphic and did not confer RTI resistance. The observed trend toward reduced likelihood of etravirine or nevirapine resistance in the presence of G335D should be investigated further.
authors: Unite d'Epidemiologie Moleculaire de la Resistance du VIH aux ARV-SEREFO-FMPOS, University of Sciences Technics and Technologies of Bamako, Bamako, Mali.
authors: Almoustapha Issiaka
authors: AI
authors: Maiga
authors: Sudhir
authors: S
authors: Penugonda
authors: Drissa
authors: D
authors: Katile
authors: Fodie
authors: F
authors: Diallo
authors: Djeneba Bocar
authors: DB
authors: Fofana
authors: Baiba
authors: B
authors: Berzins
authors: Moussa Youssouffa
authors: MY
authors: Maiga
authors: Aliou
authors: A
authors: Sylla
authors: Hamar Alassane
authors: HA
authors: Traore
authors: Anne-Genevieve
authors: AG
authors: Marcelin
authors: Vincent
authors: V
authors: Calvez
authors: Anatole
authors: A
authors: Tounkara
authors: Nobel
authors: N
authors: Bellosillo
authors: Robert
authors: R
authors: Murphy
authors: Babafemi
authors: B
authors: Taiwo
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines / Q000494:pharmacology / Q000627:therapeutic use; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008302:Mali; D009154:Mutation / Q000235:genetics; D019829:Nevirapine / Q000494:pharmacology / Q000627:therapeutic use; D010641:Phenotype; D017211:Treatment Failure
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D003841:Deoxycytidine; D019829:Nevirapine; D054303:HIV Reverse Transcriptase; D000068679:Emtricitabine; C098320:efavirenz